Company profile

iCell Gene Therapeutics

CAR-T cell therapy (private)

Privately held: no public share price · USA

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Anti-CD33 CAR T-cells
Phase 2
CD33
Acute Myeloid Leukemia
ICG318
Phase 2
BCMA / CD19Cell therapy
Inflammatory Bowel DiseaseSystemic Lupus Erythematosus
Ulcerative Colitis, Crohn's Disease
BCMA-CD19 compound CAR (cCAR) T cells
Phase 1
BCMA / CD19Cell therapy
Multiple MyelomaSystemic Lupus Erythematosus
ICG415
Phase 1
CD33 / CLL-1 (CLEC12A)
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.